Geron Corp. operates as a biotechnology company. The company is headquartered in Foster City, California and currently employs 229 full-time employees. The firm develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. The company is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Follow-Up Questions
Quelle est la performance du prix de l'action GERN ?
Le prix actuel de GERN est de $1.31, il a decreased de 0.75% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Geron Corp ?
Geron Corp appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Geron Corp ?
La capitalisation boursière actuelle de Geron Corp est de $835.8M
Est-ce que Geron Corp est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 10 analystes ont établi des notations d'analystes pour Geron Corp, y compris 5 achat fort, 6 achat, 3 maintien, 1 vente et 5 vente forte
